Segment and Geographic Information - Segment Reporting (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 23, 2026	Jan. 24, 2025	Jan. 23, 2026	Jan. 24, 2025
Segment Reporting Information [Line Items]
Net sales	$ 9,017	$ 8,292	$ 26,557	$ 24,610
Cost of products sold, excluding amortization of intangible assets	3,261	2,779	9,323	8,485
Research and development expense	722	675	2,202	2,048
Selling, general, and administrative expense	2,956	2,717	8,727	8,129
Reportable segment operating profit	1,464	1,646	4,594	4,519
Other non-operating income, net	121	72	247	403
Amortization of intangible assets	(441)	(416)	(1,364)	(1,243)
Restructuring and associated costs	(172)		(251)
Certain litigation charges, net	(62)	(22)	(89)	(104)
Income before income taxes	1,404	1,540	4,302	4,367
Operating Segments
Segment Reporting Information [Line Items]
Net sales	8,985	8,260	26,417	24,593
Cost of products sold, excluding amortization of intangible assets	3,173	2,748	9,197	8,350
Research and development expense	720	672	2,200	2,038
Selling, general, and administrative expense	2,897	2,701	8,591	8,067
Other segment items	3	(12)	(17)	(27)
Reportable segment operating profit	2,192	2,151	6,446	6,166
Segment reconciling items
Segment Reporting Information [Line Items]
Other adjustments			39	(90)
Currency and other	(13)	4	(108)	(44)
Interest expense, net	(181)	(179)	(539)	(555)
Other non-operating income, net	121	72	247	403
Amortization of intangible assets	(441)	(416)	(1,364)	(1,243)
Restructuring and associated costs	(172)	(46)	(251)	(154)
Acquisition and divestiture-related items	(38)	(28)	(96)	(15)
Certain litigation charges, net	(62)	(22)	(89)	(104)
Medical device regulations		(11)		(38)
Cardiovascular | Operating Segments
Segment Reporting Information [Line Items]
Net sales	3,457	3,037	10,179	9,145
Cost of products sold, excluding amortization of intangible assets	1,159	964	3,426	3,013
Research and development expense	284	248	863	761
Selling, general, and administrative expense	1,129	1,010	3,331	3,009
Other segment items	(14)	(14)	(45)	(27)
Reportable segment operating profit	899	828	2,604	2,389
Neuroscience | Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,558	2,458	7,536	7,226
Cost of products sold, excluding amortization of intangible assets	815	712	2,308	2,108
Research and development expense	153	152	477	463
Selling, general, and administrative expense	841	820	2,546	2,462
Other segment items	12	12	23	19
Reportable segment operating profit	737	762	2,183	2,173
Medical Surgical | Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,173	2,072	6,428	6,196
Cost of products sold, excluding amortization of intangible assets	867	788	2,512	2,385
Research and development expense	174	164	523	496
Selling, general, and administrative expense	628	605	1,861	1,805
Other segment items	6	4	9	14
Reportable segment operating profit	499	512	1,523	1,496
Diabetes | Operating Segments
Segment Reporting Information [Line Items]
Net sales	796	694	2,274	2,027
Cost of products sold, excluding amortization of intangible assets	332	284	951	844
Research and development expense	109	108	337	317
Selling, general, and administrative expense	300	266	853	790
Other segment items	(2)	(15)	(3)	(33)
Reportable segment operating profit	57	50	136	108
Other operating segment | Operating Segments
Segment Reporting Information [Line Items]
Net sales	32	32	101	106
Other adjustments			39	(90)
Reportable segment operating profit	$ (1)	$ 13	$ 18	$ 39